ERBB2 and breast cancer: Among 34 HER2+ and 39 TN breast cancers (Additional file 2: Table S1), univariately, the take rate was found to be: greater in grade 3 tumors than grade 1–2 tumors (p = 0.0003; difference = 46.6%; 95% CI: 29.9–63.3%); greater in NSG mice than in NOD-SCID mice (p = 0.0012; difference = 39.9%; 95% CI: 17.7–62.0%); and greater in TN tumors than HER2+ tumors (p = 0.0348; difference = 24.8%; 95% CI: 3.2–46.4%).